Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma

Summary

In this study with a modified 3+3 dose finding design, a safe and tolerable dose of TKI258 in patients with relapsed glioblastoma should be established.

Timeline

Start

2013-10

Primary completion

2016-11

Completion

2016-11

Drugs

Indications